Novo Nordisk plans to submit weekly growth hormone for approval in H1
Novo Nordisk and Ascendis Pharma could soon face each other on the market for treating children with growth hormone deficiency, as the Danish pharmaceutical giant is intending to file its candidate for approval in the US where latter company is already present.
by MARKETWIRE & MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen
Novo Nordisk is planning to submit its once-weekly growth hormone deficiency (GHD) treatment for children, Sogroya, for regulatory approval in the first half of 2022, the company announces in its financial report on Wednesday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Ascendis Pharma extends trial of growth hormone in adults
For subscribers
.jpg&w=384&q=75)
